Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOther Non-Current AssetsPayablesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fennec Pharmaceuticals (FENC) Finished Goods (2022 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed Finished Goods for 4 consecutive years, with $2.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Finished Goods rose 120.18% year-over-year to $2.5 million, compared with a TTM value of $2.5 million through Sep 2025, up 120.18%, and an annual FY2024 reading of $1.1 million, down 50.83% over the prior year.
  • Finished Goods was $2.5 million for Q3 2025 at Fennec Pharmaceuticals, up from $2.2 million in the prior quarter.
  • Across five years, Finished Goods topped out at $2.5 million in Q3 2025 and bottomed at $576000.0 in Q4 2022.
  • Average Finished Goods over 4 years is $1.6 million, with a median of $1.6 million recorded in 2023.
  • The sharpest move saw Finished Goods soared 274.31% in 2023, then plummeted 50.83% in 2024.
  • Year by year, Finished Goods stood at $576000.0 in 2022, then skyrocketed by 274.31% to $2.2 million in 2023, then tumbled by 50.83% to $1.1 million in 2024, then surged by 133.68% to $2.5 million in 2025.
  • Business Quant data shows Finished Goods for FENC at $2.5 million in Q3 2025, $2.2 million in Q2 2025, and $1.4 million in Q1 2025.